Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

While the link between TNF inhibitor use during pregnancy/postpartum and serious infection risk was not statistically significant, an increased risk cannot be ruled out.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The median survival time of first-line anti-TNF therapy ...

WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...

TNF inhibitors were used by 64% of pregnant women with inflammatory diseases through all trimesters. Those with continuous use through all trimesters had reduced use of corticosteroids postpartum.

May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...